Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Rapid progression to AML in a patient with germline GATA2 mutation and acquired NRAS Q61K mutation.

McReynolds LJ, Zhang Y, Yang Y, Tang J, Mulé M, Hsu AP, Townsley DM, West RR, Zhu J, Hickstein DD, Holland SM, Calvo KR, Hourigan CS.

Leuk Res Rep. 2019 Jun 10;12:100176. doi: 10.1016/j.lrr.2019.100176. eCollection 2019.

2.

Heterogeneity in refractory acute myeloid leukemia.

Horibata S, Gui G, Lack J, DeStefano CB, Gottesman MM, Hourigan CS.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10494-10503. doi: 10.1073/pnas.1902375116. Epub 2019 May 7.

PMID:
31064876
3.

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab.

Lai C, Ranpura V, Wu C, Olnes MJ, Parikh AR, Shenoy A, Thompson J, Weinstein B, Scheinberg P, Barrett AJ, Desmond R, Young NS, Hourigan CS.

Blood Adv. 2019 Apr 9;3(7):980-983. doi: 10.1182/bloodadvances.2018030411. No abstract available. Erratum in: Blood Adv. 2019 Jun 11;3(11):1657.

4.

The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.

Palangat M, Anastasakis DG, Fei DL, Lindblad KE, Bradley R, Hourigan CS, Hafner M, Larson DR.

Genes Dev. 2019 May 1;33(9-10):482-497. doi: 10.1101/gad.319590.118. Epub 2019 Mar 6.

PMID:
30842218
5.

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Wong HY, Sung AD, Lindblad KE, Sheela S, Roloff GW, Rizzieri D, Goswami M, Mulé MP, Ramos NR, Tang J, Thompson J, DeStefano CB, Romero K, Dillon LW, Kim DY, Lai C, Hourigan CS.

Front Oncol. 2019 Jan 15;8:669. doi: 10.3389/fonc.2018.00669. eCollection 2018.

6.

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

McReynolds LJ, Yang Y, Yuen Wong H, Tang J, Zhang Y, Mulé MP, Daub J, Palmer C, Foruraghi L, Liu Q, Zhu J, Wang W, West RR, Yohe ME, Hsu AP, Hickstein DD, Townsley DM, Holland SM, Calvo KR, Hourigan CS.

Leuk Res. 2019 Jan;76:70-75. doi: 10.1016/j.leukres.2018.11.013. Epub 2018 Dec 4.

PMID:
30578959
7.

Refining AML outcome prediction.

Hourigan CS, Gale RP, Walter RB.

Leukemia. 2019 Feb;33(2):283-284. doi: 10.1038/s41375-018-0317-4. Epub 2018 Dec 14. No abstract available.

PMID:
30552400
8.

Pathogenic TERT promoter variants in telomere diseases.

Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW, Clé DV, Santana BA, Pirooznia M, Ibanez MDPF, Townsley DM, Kajigaya S, Hourigan CS, Cooper JN, Calado RT, Young NS.

Genet Med. 2019 Jul;21(7):1594-1602. doi: 10.1038/s41436-018-0385-x. Epub 2018 Dec 7.

9.

Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry.

Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, Dillon LW, McCoy JP, Hourigan CS.

JCI Insight. 2018 Dec 6;3(23). pii: 124928. doi: 10.1172/jci.insight.124928.

10.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2019 May 1;125(9):1470-1481. doi: 10.1002/cncr.31896. Epub 2018 Nov 30.

11.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

12.

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.

Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK.

Neurosurgery. 2019 Apr 1;84(4):945-953. doi: 10.1093/neuros/nyy392.

PMID:
30189044
13.

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.

Dillon LW, Hayati S, Roloff GW, Tunc I, Pirooznia M, Mitrofanova A, Hourigan CS.

Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.

14.

Leukaemia risk associated with low-dose radiation.

Hourigan CS, Savani BN.

Lancet Haematol. 2018 Aug;5(8):e324-e325. doi: 10.1016/S2352-3026(18)30106-6. Epub 2018 Jul 17. No abstract available.

15.

Personalizing initial therapy in acute myeloid leukemia: incorporating novel agents into clinical practice.

DeStefano CB, Hourigan CS.

Ther Adv Hematol. 2018 May;9(5):109-121. doi: 10.1177/2040620718761778. Epub 2018 Mar 27. Review.

16.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ.

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Review.

17.

The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Buccisano F, Hourigan CS, Walter RB.

Curr Hematol Malig Rep. 2017 Dec;12(6):547-556. doi: 10.1007/s11899-017-0420-z. Review.

PMID:
29027628
18.

NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.

Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, Odunsi K, Karpf AR, Hourigan CS, Nemeth MJ.

Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. doi: 10.1158/1078-0432.CCR-17-1792. Epub 2017 Sep 25.

19.

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.

Roloff GW, Lai C, Hourigan CS, Dillon LW.

J Clin Med. 2017 Sep 19;6(9). pii: E87. doi: 10.3390/jcm6090087. Review.

20.

Haplo, we have a problem.

Hourigan CS.

Blood. 2017 Sep 7;130(10):1180. doi: 10.1182/blood-2017-07-795062. No abstract available.

21.

Successful salvage chemotherapy and allogeneic transplantation of an acute myeloid leukemia patient with disseminated Fusarium solani infection.

Sheela S, Ito S, Strich JR, Manion M, Montemayor-Garcia C, Wang HW, Oetjen KA, West KA, Barrett AJ, Parta M, Gea-Banacloche J, Holland SM, Hourigan CS, Lai C.

Leuk Res Rep. 2017 Jul 18;8:4-6. doi: 10.1016/j.lrr.2017.07.001. eCollection 2017.

22.

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS.

J Transl Med. 2017 Jul 10;15(1):155. doi: 10.1186/s12967-017-1252-2.

23.

Immunological effects of hypomethylating agents.

Lindblad KE, Goswami M, Hourigan CS, Oetjen KA.

Expert Rev Hematol. 2017 Aug;10(8):745-752. doi: 10.1080/17474086.2017.1346470. Epub 2017 Jul 3. Review.

24.

A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission.

Cheng MJ, Smith BD, Hourigan CS, Gojo I, Pratz KW, Blackford AL, Mehta AK, Smith TJ.

J Palliat Med. 2017 Nov;20(11):1267-1273. doi: 10.1089/jpm.2017.0069. Epub 2017 May 24.

25.

Measurable residual disease testing in acute myeloid leukaemia.

Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB.

Leukemia. 2017 Jul;31(7):1482-1490. doi: 10.1038/leu.2017.113. Epub 2017 Apr 7. Review.

PMID:
28386105
26.

Editorial: Targets for Immunotherapy in Acute Leukemia.

Hourigan CS.

Curr Drug Targets. 2017;18(3):256. doi: 10.2174/1389450117999151116144835. No abstract available.

27.

Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Percival ME, Lai C, Estey E, Hourigan CS.

Blood Rev. 2017 Jul;31(4):185-192. doi: 10.1016/j.blre.2017.01.003. Epub 2017 Feb 2. Review.

28.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.

29.

Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Hourigan CS, Haferlach T, Hokland P.

N Engl J Med. 2016 Dec 1;375(22):2204. doi: 10.1056/NEJMc1612872. No abstract available.

PMID:
27959750
30.

Accurate Medicine: Indirect Targeting of NPM1-Mutated AML.

Hourigan CS, Aplan PD.

Cancer Discov. 2016 Oct;6(10):1087-1089.

31.

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17.

32.

When the Minimal Becomes Measurable.

Hourigan CS, Goswami M, Battiwalla M, Barrett AJ, Sheela S, Karp JE, Lai C.

J Clin Oncol. 2016 Jul 20;34(21):2557-8. doi: 10.1200/JCO.2016.67.6395. Epub 2016 May 16. No abstract available.

PMID:
27185839
33.

Precision medicine for acute myeloid leukemia.

Lai C, Karp JE, Hourigan CS.

Expert Rev Hematol. 2016 Jan;9(1):1-3. doi: 10.1586/17474086.2016.1107471. Epub 2015 Oct 30.

34.

Identification of novel microRNA signatures linked to acquired aplastic anemia.

Hosokawa K, Muranski P, Feng X, Keyvanfar K, Townsley DM, Dumitriu B, Chen J, Kajigaya S, Taylor JG, Hourigan CS, Barrett AJ, Young NS.

Haematologica. 2015 Dec;100(12):1534-45. doi: 10.3324/haematol.2015.126128. Epub 2015 Sep 9.

35.

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.

Anand A, Anandi P, Jain NA, Lu K, Dunavin N, Hourigan CS, Le RQ, Chokshi PD, Ito S, Stroncek DF, Sabatino M, Barrett AJ, Battiwalla M.

Support Care Cancer. 2016 Feb;24(2):815-822. doi: 10.1007/s00520-015-2848-9. Epub 2015 Jul 21.

36.

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Hokland P, Ommen HB, Mulé MP, Hourigan CS.

Semin Hematol. 2015 Jul;52(3):184-92. doi: 10.1053/j.seminhematol.2015.04.001. Epub 2015 Apr 7. Review.

37.

Acute Myeloid Leukemia: Introduction.

Hourigan CS.

Semin Hematol. 2015 Jul;52(3):149. doi: 10.1053/j.seminhematol.2015.04.004. Epub 2015 Apr 7. No abstract available.

PMID:
26111461
38.

Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation.

Le RQ, Tian X, Jain NA, Lu K, Ito S, Draper DA, Anandi P, Hourigan CS, Dunavin N, John Barrett A, Battiwalla M.

Bone Marrow Transplant. 2015 Aug;50(8):1138-40. doi: 10.1038/bmt.2015.112. Epub 2015 May 18. No abstract available.

PMID:
25985051
39.

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.

Ramos NR, Mo CC, Karp JE, Hourigan CS.

J Clin Med. 2015 Apr;4(4):665-95. doi: 10.3390/jcm4040665.

40.

Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.

Goswami M, Hourigan CS.

Curr Drug Targets. 2017;18(3):296-303. doi: 10.2174/1389450116666150223120005. Review.

41.

A multigene array for measurable residual disease detection in AML patients undergoing SCT.

Goswami M, McGowan KS, Lu K, Jain N, Candia J, Hensel NF, Tang J, Calvo KR, Battiwalla M, Barrett AJ, Hourigan CS.

Bone Marrow Transplant. 2015 May;50(5):642-51. doi: 10.1038/bmt.2014.326. Epub 2015 Feb 9.

42.

Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.

Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM.

Bone Marrow Transplant. 2015 Feb;50(2):189-196. doi: 10.1038/bmt.2014.249. Epub 2014 Nov 10.

43.

Adult Acute Myeloid Leukemia Long-term Survivors.

Cheng MJ, Hourigan CS, Smith TJ.

J Leuk (Los Angel). 2014 Apr 10;2(2). pii: 26855.

44.

Next generation MRD.

Hourigan CS.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1259-60. doi: 10.1016/j.bbmt.2014.07.002. Epub 2014 Jul 10. No abstract available.

45.

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia.

Purev E, Dumitriu B, Hourigan CS, Young NS, Townsley DM.

Leuk Res Rep. 2014 Jun 11;3(2):46-8. doi: 10.1016/j.lrr.2014.04.002. eCollection 2014.

46.

The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.

Jain NA, Lu K, Ito S, Muranski P, Hourigan CS, Haggerty J, Chokshi PD, Ramos C, Cho E, Cook L, Childs R, Battiwalla M, Barrett AJ.

Cytotherapy. 2014 Jul;16(7):927-33. doi: 10.1016/j.jcyt.2014.02.010. Epub 2014 May 13.

47.

Reprint of: Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Hourigan CS, McCarthy P, de Lima M.

Biol Blood Marrow Transplant. 2014 Feb;20(2 Suppl):S8-S17. doi: 10.1016/j.bbmt.2014.01.005.

48.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.

Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. No abstract available.

49.

Personalized therapy for acute myeloid leukemia.

Hourigan CS, Karp JE.

Cancer Discov. 2013 Dec;3(12):1336-8. doi: 10.1158/2159-8290.CD-13-0832.

50.

Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.

Hourigan CS, McCarthy P, de Lima M.

Biol Blood Marrow Transplant. 2014 Feb;20(2):154-63. doi: 10.1016/j.bbmt.2013.11.017. Epub 2013 Nov 27. Review.

Supplemental Content

Loading ...
Support Center